Reading time: 2 – 3 minutes
A roundup of five research studies on cancer biomarkers that were presented earlier this week at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida.
- Target for Lung Cancer Chemoprevention Identified
Scientists at the University of Colorado Cancer Center presented data on a biomarker for measuring the success of lung cancer chemoprevention. Measurements of endobronchial dysplasia, abnormal cell development that can lead to lung cancer, can predict how well a chemoprevention agent is working.
- Protein Test Detects Early-stage, Asbestos-related Pulmonary Cancer
NCI researchers described an assay using aptamer proteomic technology to test 19 biomarkers of malignant pleural mesothelioma and believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos.
- Breast Milk May Provide a Personalized Screen of Breast Cancer Risk
University of Massachusetts Amherst researchers presented data demonstrating that breast cancer risk can be assessed by examining the methylation status of three genes – RASSF1, GSTP1 and SFRP1 – from epithelial cells found in breast milk.
- BATTLE Researchers Identify New Biomarkers for EGFR Inhibition
Researchers working on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial, or BATTLE trial, presented data that showing an epithelial-to-mesenchymal signature and the presence of a novel five gene signature including LCN2 that predicts response to erlotinib and includes patients with wild-type EGFR.
- Serum Test Could Identify Lung Cancer in People Who Never Smoked
Celera scientists described a panel of biomarkers that appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked with an 83% sensitivity/specificity.